NCT03398200已完成2 期
HBO Effects on Blood Count Recovery and Post-transplant Outcomes Following High-dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma
Omar Aljitawi3 个研究点 分布在 1 个国家目标入组 99 人开始时间: 2018年5月10日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 99
- 试验地点
- 3
- 主要终点
- Time From Transplant to Neutrophil Count Recovery
研究概览
简要总结
Patients with Multiple Myeloma who are considered for high-dose therapy and autologous transplantation at the bone marrow transplant clinic at the Wilmot Cancer Institute (WCI) will be be approached to participate in this trial. Eligible patients who choose to participate will be randomized so that half receive one hyperbaric oxygen therapy session prior to hematopoetic stem cell infusion and half will not. All subjects will have their blood counts monitored closely and time to count recovery will be compared between the two groups.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntary written informed consent.
- •Multiple myeloma diagnosis applying the latest criteria by International Working Group. Patients should have received myeloma-directed induction therapy with appropriate response (partial response or better) in newly diagnosed myeloma patients. Multiple myeloma patients who relapse following induction therapy or following prior autologous hematopoietic stem cell transplant are also eligible as far as remission following their first autologous hematopoietic stem cell transplant lasted 12 months or more.
- •Patients who are considered for high-dose therapy and autologous transplantation at the bone marrow transplant clinic at Wilmot Cancer Institute will be screened for eligibility to enroll in this study and if eligible will be approached to participate. Eligible patients will have the chance to tour the hyperbaric oxygen facility prior to signing the consent form.
- •Subjects must be ≥ 18 years old and ≤ 75 years old.
- •Karnofsky performance status (KPS) of ≥ 70%.
- •Adequate hepatic, cardiac and pulmonary function to be eligible for transplant. Minimum criteria include:
- •- Alanine aminotransferase (ALT), aspartate aminotransferase (AST): < 4x institutional upper limit of normal (IULN)
- •- Total bilirubin: ≤ 2.0 mg/dL
- •- Ejection fraction (EF) measured by two-dimensional echocardiography (2D-ECHO) or multigated acquisition (MUGA) scan of ≥ 45%
- •- Forced expiratory volume at one second (FEV1), forced vital capacity (FVC), and diffusing capacity of lung for carbon monoxide (DLCO) ≥ 50% of predicted value (corrected to serum hemoglobin)
- •- Electrocardiogram (EKG) with no clinically significant arrhythmia.
- •Patients should have New York Heart Association (NYHA) Functional Classification, class I or II (No or mild limitation during ordinary activity).
- •Patients should be evaluated for fitness for hyperbaric oxygen therapy by a hyperbaric oxygen trained medical professional who is not part of the study team prior to starting preparative regimen.
- •Women of child-bearing potential should have a negative urine pregnancy test within 4 weeks of starting preparative regimen.
- •Women of child-bearing potential and men with partners of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days following completion of therapy. Should a woman or partner become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician and the investigator immediately.
- •A woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- •- Has not undergone a hysterectomy or bilateral oophorectomy; or
- •- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
排除标准
- •Pregnant or breastfeeding
- •Severe chronic obstructive pulmonary disease requiring oxygen supplementation
- •History of spontaneous pneumothorax
- •Active ear/sinus infection
- •History of sinus or ear surgery, excluding myringotomy or ear tubes
- •Claustrophobia
- •History of seizures
- •Evidence of pneumothorax or significant pulmonary fibrosis on chest imaging
- •Prior chest surgery or irradiation
- •Patients who had intrathecal chemotherapy within 2 weeks of starting preparative regimen or cranial irradiation within 4 weeks of starting preparative regimen
- •Active infection (viral, fungal, and/or bacterial)
- •Positive screening for Hepatitis A, B, or C indicating an ongoing infection
研究组 & 干预措施
Hyperbaric Oxygen Therapy
Experimental
Subjects on the experimental arm will receive 90 minutes of hyperbaric oxygen therapy approximately six hours prior to hematopoietic stem cell infusion.
干预措施: Hyperbaric Oxygen Therapy (Biological)
No Hyperbaric Oxygen Therapy
Active Comparator
Subjects on the reference arm will not receive hyperbaric oxygen therapy prior to hematopoietic stem cell infusion.
干预措施: No Hyperbaric Oxygen Therapy (Other)
结局指标
主要结局
Time From Transplant to Neutrophil Count Recovery
时间窗: 100 days
Time from transplant to neutrophil recovery was measured as the first day of absolute neutrophil count \>=0.5 thou/ul after nadir.
次要结局
- Time From Transplant to Absolute Lymphocyte Recovery(100 days)
- Number of Days of Granulocyte Colony-stimulating Factor(100 days)
- Number of Units of Packed Red Blood Cells Received(100 days)
- Length of Hospital Stay(100 days)
- Percentage of Participants With Progressive Free Survival(1 year)
研究者
Omar Aljitawi
Associate Professor of Hematology/Oncology
University of Rochester
研究点 (3)
Loading locations...
相似试验
终止
2 期
BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft ToleranceKidney TransplantationNCT02029638National Institute of Allergy and Infectious Diseases (NIAID)4
招募中
不适用
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple MyelomaMultiple MyelomaNCT03127761Center for International Blood and Marrow Transplant Research544
招募中
不适用
Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation, Cellular Therapy, or Gene TherapyHematopoietic Stem Cell TransplantationTissue DonorsCellular Immunotherapy, AdoptiveGenetic TherapyNCT03000244National Cancer Institute (NCI)2,000
Unknown
不适用
Clinical Implication of Bone Marrow Perfusion Patterns Imaged by Dynamic MRI in Multiple MyelomaMultiple Myeloma, Newly DiagnosedNCT00166855National Taiwan University Hospital40
招募中
4 期
BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to OndansetronNCT04150614University of Illinois at Chicago90